ANI Pharmaceuticals Inc. (NASDAQ:ANIP) and Prothena Corporation plc (NASDAQ:PRTA), both competing one another are Biotechnology companies. We will contrast their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ANI Pharmaceuticals Inc.||70||4.05||N/A||1.15||73.62|
|Prothena Corporation plc||11||424.83||N/A||-3.20||0.00|
We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of ANI Pharmaceuticals Inc. and Prothena Corporation plc.
Table 2 demonstrates the net margins, return on equity and return on assets of ANI Pharmaceuticals Inc. and Prothena Corporation plc.
|Net Margins||Return on Equity||Return on Assets|
|ANI Pharmaceuticals Inc.||0.00%||7%||3.1%|
|Prothena Corporation plc||0.00%||-38.4%||-25%|
Volatility & Risk
ANI Pharmaceuticals Inc.’s volatility measures that it’s 116.00% more volatile than Standard and Poor’s 500 due to its 2.16 beta. From a competition point of view, Prothena Corporation plc has a 2.24 beta which is 124.00% more volatile compared to Standard and Poor’s 500.
ANI Pharmaceuticals Inc.’s Current Ratio is 0.9 while its Quick Ratio is 0.7. On the competitive side is, Prothena Corporation plc which has a 27.9 Current Ratio and a 27.9 Quick Ratio. Prothena Corporation plc is better positioned to pay off short and long-term obligations compared to ANI Pharmaceuticals Inc.
The next table highlights the shown recommendations and ratings for ANI Pharmaceuticals Inc. and Prothena Corporation plc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|ANI Pharmaceuticals Inc.||0||0||3||3.00|
|Prothena Corporation plc||0||0||0||0.00|
ANI Pharmaceuticals Inc.’s upside potential is 4.09% at a $75 average target price.
Insider & Institutional Ownership
ANI Pharmaceuticals Inc. and Prothena Corporation plc has shares owned by institutional investors as follows: 86.2% and 92.7%. ANI Pharmaceuticals Inc.’s share owned by insiders are 3.3%. Competitively, 90.1% are Prothena Corporation plc’s share owned by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|ANI Pharmaceuticals Inc.||1.72%||2.27%||20.43%||55.98%||25.49%||87.89%|
|Prothena Corporation plc||-6.49%||-8.86%||-7.42%||-20.34%||-36.28%||-9.13%|
For the past year ANI Pharmaceuticals Inc. had bullish trend while Prothena Corporation plc had bearish trend.
On 7 of the 9 factors ANI Pharmaceuticals Inc. beats Prothena Corporation plc.
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for pain; Propafenone to treat arrhythmia; Propranolol ER and Inderal LA for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating ParkinsonÂ’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in DÃºn Laoghaire, Ireland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.